Cubist Systematic Strategies LLC Acquires Shares of 54,273 AnaptysBio, Inc. (NASDAQ:ANAB)

Cubist Systematic Strategies LLC bought a new position in AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 54,273 shares of the biotechnology company’s stock, valued at approximately $1,360,000. Cubist Systematic Strategies LLC owned about 0.20% of AnaptysBio as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ensign Peak Advisors Inc lifted its holdings in AnaptysBio by 74.4% during the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock worth $1,898,000 after acquiring an additional 32,313 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of AnaptysBio by 52.4% in the 2nd quarter. Renaissance Technologies LLC now owns 152,702 shares of the biotechnology company’s stock worth $3,827,000 after buying an additional 52,502 shares during the last quarter. Headlands Technologies LLC grew its position in AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 2,900 shares during the period. TD Asset Management Inc increased its holdings in AnaptysBio by 67.3% during the second quarter. TD Asset Management Inc now owns 37,800 shares of the biotechnology company’s stock worth $947,000 after buying an additional 15,200 shares during the last quarter. Finally, Rhumbline Advisers raised its position in AnaptysBio by 1.8% in the second quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock worth $745,000 after acquiring an additional 525 shares during the period.

Wall Street Analysts Forecast Growth

ANAB has been the subject of several research analyst reports. JPMorgan Chase & Co. raised their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of AnaptysBio in a research note on Wednesday, August 14th. Wedbush reiterated an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a research note on Thursday, September 26th. Finally, Truist Financial boosted their price objective on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.10.

AnaptysBio Trading Up 3.9 %

ANAB stock opened at $34.81 on Wednesday. The firm has a 50 day moving average of $35.64 and a 200-day moving average of $28.25. The firm has a market capitalization of $950.97 million, a P/E ratio of -5.67 and a beta of -0.29. AnaptysBio, Inc. has a 12 month low of $13.36 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The business had revenue of $10.97 million for the quarter, compared to analysts’ expectations of $25.85 million. Sell-side analysts predict that AnaptysBio, Inc. will post -6.84 EPS for the current year.

Insider Transactions at AnaptysBio

In other news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the stock in a transaction on Wednesday, August 14th. The shares were acquired at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the transaction, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In related news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the completion of the sale, the insider now directly owns 11,618 shares in the company, valued at approximately $406,630. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the stock in a transaction on Wednesday, August 14th. The stock was bought at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the transaction, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 33,940 shares of company stock valued at $1,251,836. Insiders own 33.70% of the company’s stock.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.